Lineage Cell Therapeutics Inc (Lineage) formerly BioTime Inc, is a clinical-stage biotechnology company that focuses on the development of novel allogeneic cell therapies to address unmet medical needs. The company's programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. Lineage designs, develops, manufactures, and tests specialized human cells with functions similar or identical to cells found naturally in the human body.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company R&D efforts focus on the development of its Cell Therapy technology product candidates for the treatment of various therapeutic indications. Lineage has undertaken several R&D initiatives, including the development of OPC1, a product relevant to neural cells such as oligodendrocyte progenitor cells. The company owns several patent families related to this, including those acquired from Geron Corp. Lineage also has pending patent applications for the ANP1 program, and rights to three patent families for the PNC1 program. Additionally, the company has numerous patents and applications relevant to dendritic cells, and a patent family related to immunogenic compositions. Its Lineage Platform uses pluripotent stem cell lines to develop and manufacture specialized human cells for use in cell-based therapy. As of December 2024, the company owned or licensed several hundred US and international patents and patent applications, including nine patent families owned by the company, 10 pending patent applications for the ANP1 program, two patent families for the PNC1 program, and numerous patents and applications relevant to dendritic cells. The company's pipeline products include OPC1, ANP1, and PNC1. It has a technology alliance with Hadasit and Cell Cure, and has received funding from CIRM, a state agency established to fund stem cell research. In FY2024, the company spent US$12.4 million on its R&D activities.